



Financial Tear Sheet

Corporate Profile

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the future treatment of solid and hematologic cancers. Sunesis has built an experienced cancer drug development organization committed to improving the lives of people with cancer. The company is focused on advancing its novel kinase-inhibitor pipeline, with an emphasis on establishing proof of concept that its oral non-covalent BTK-inhibitor, SNS-062, treats ibrutinib-resistant chronic lymphocytic leukemia. Sunesis is also supporting investigator-led studies of vosaroxin in acute myeloid leukemia.

Stock Quote

SNSS (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$2.04
Change (%)	▼ 0.02 (0.97%)
Volume	45,450
52 Week Low	\$2.00
Market Cap	\$47,966,916
Rolling EPS	-1.86
PE Ratio	N/A
Shares Outstanding	23,513,194

Data as of 09/20/17 12:39 p.m. ET

Stock Chart



Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent News

Date	Title
08/31/17	Sunesis to Present at Upcoming Investor Conferences
07/27/17	Sunesis Pharmaceuticals Reports Second Quarter 2017 Financial

Upcoming Events

Date	Title
09/27/17	Sunesis Pharmaceuticals, Inc. at Cantor Fitzgerald Global Healthcare Conference


Results and Recent Highlights

07/24/17 Sunesis to Host Conference Call on July 27th to Discuss Second Quarter 2017 Financial Results and Recent Highlights

Analyst Ratings

1-Strong Buy	1
2-Buy	0
3-Hold	2
4-Underperform	0
5-Sell	0

Mean Recommendation: 2.3



SEC Filings

Filing Date	Form
08/28/17	8-K
07/27/17	10-Q
07/27/17	8-K
07/12/17	4

Investor and Media Inquiries:

Maeve Conneighton

Argot Partners
206.899.4940

Dan Swisher

Sunesis Pharmaceuticals, Inc.
650-266-3715

Board of Directors

Steve R. Carchedi	Director
Steven B. Ketchum, Ph.D.	Director
Dayton Misfeldt	Director
Geoffrey M. Parker	Director
Homer L. Pearce, Ph.D.	Director
David C. Stump, M.D.	Director
Daniel N. Swisher, Jr.	Chief Executive Officer and President
James W. Young, Ph.D.	Chairman

Management

Daniel N. Swisher, Jr.	Chief Executive Officer and President
Judith A. Fox, Ph.D.	Chief Scientific Officer
Parvinder S. Hyare	Vice President, Global Oncology Operations
Gene Jamieson	Vice President, Technical Operations
Jennifer A. Smith, Ph.D.	Vice President, Biometrics
Deborah A. Thomas, Ph.D.	Senior Vice President, Regulatory Affairs, Quality Assurance, and Nonclinical Development